The blog

News & Updates

Clinical trial results, TGA regulatory progress and research updates on retatrutide and the wider peptide space — explained for Australians.

All Retatrutide BPC-157 TB-500 GHK-Cu Human Growth Hormone Tesamorelin Semax Selank Epithalon NAD+SS-31 SLU-PP-332

13 September 2026 · ss-31 · elamipretide · mitochondria · longevity · peptide-research

SS-31 Research: The XPRIZE Bet on Mitochondrial Ageing

SS-31 (elamipretide) is an XPRIZE Healthspan finalist compound. What the mouse ageing data, the 2026 HFpEF study and the ARTG status actually show.

10 September 2026 · ss-31 · elamipretide · peptides · clinical-trials · tga

SS-31 Research: The Verdict Now Rests on the Eye

SS-31 (elamipretide) research in 2026: one US approval, one failed phase 3, and a dry AMD trial reading out. What the evidence shows and its Australia status.

Stay informed

Be first to know.
When it reaches Australia.

Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:

The latest clinical trial results and news from Eli Lilly
Updates on TGA regulatory progress in Australia
How and where to access Retatrutide when it becomes available
Occasional information from retatrutide.net.au and our affiliated partners

TGA review expected 2027 — subscribers hear the moment the status changes.

Get the free guide + updates

Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.

News & Updates

SS-31 Research: The XPRIZE Bet on Mitochondrial Ageing

SS-31 Research: The Verdict Now Rests on the Eye

Be first to know.When it reaches Australia.

Be first to know.
When it reaches Australia.